SHS invests in Simulands AG

The German life science and medtech investor SHS Gesellschaft für Beteiligungsmanagement mbH has made a EUR 10 million investment in Simulands AG, a Zurich-based manufacturer of simulation devices for medical training of cardiovascular interventions. The fast-growing Simulands AG has established itself as a leading provider of medical simulation training in the field of structural cardiac interventions. SHS' investment aims to accelerate the commercialization of this early-stage company and to help it revolutionize cardiovascular education and training.

VISCHER advised SHS on all legal aspects of this transaction. The VISCHER team was led by Christian Gutzwiller (Senior Associate, Corporate/M&A) and Dr. Jürg Luginbühl (Partner, Corporate/M&A) and included Dr. Stefan Kohler (Partner, IP/Regulatory), Elias Mühlemann (Managing Associate, IP/Data & Privacy), Dan Pruschy (Associate, IP/Regulatory) and Gordana Nisevic (Corporate/M&A).

Categories: Corporate and commercial, Intellectual Property, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk